BioGenerator Ventures

What BioGenerator Ventures does

BioGenerator Ventures is the venture creation and investment arm of BioSTL, a St. Louis-based nonprofit bioscience ecosystem organization. Founded in 2003/2004, the firm creates, builds, and invests in early-stage life sciences companies solving problems in human health and agriculture, operating from its 4340 Duncan Avenue headquarters with facilities co-located at the Cortex Innovation Community and the 39N agtech district. BioGenerator typically serves as the first professional capital into portfolio companies and syndicates with a global network of 250+ venture capital, private equity, and strategic investors including Novo Holdings, NEA, ARCH Venture Partners, GV, Leaps by Bayer, AbbVie Ventures, and Roche Venture Fund.

The firm's core offering combines catalytic investment capital with the proprietary BioGenerator Labs engine — a suite of company-building resources including coaching from Executives in Residence, SBIR/STTR non-dilutive grant training and acquisition support, shared capital equipment, innovative wet laboratory space at Cortex and 39N, talent recruitment via a VC Fellow program, and investor relations support. BioGenerator has cumulatively invested more than $50 million across 130+ portfolio companies (Geneoscopy, Benson Hill, MediBeacon, Wugen, SentiAR, CoverCress, Plastomics, Canopy Biosciences, Confluence Life Sciences, DiSARM, Solis Agrosciences), with portfolio companies attracting roughly $2.8–3 billion in follow-on capital — approximately a 60X leverage on direct investment. Demonstrated exits include Galera Therapeutics' 2019 $60M NASDAQ IPO, Canopy Biosciences' 2020 acquisition by Bruker, Benson Hill's 2021 $2B SPAC merger on the NYSE, CoverCress's 2022 acquisition of a 65% controlling interest by Bayer, Confluence Life Sciences' acquisition by Aclaris Therapeutics, DiSARM's acquisition by Eli Lilly for up to $1.2 billion, and CareSignal's acquisition by Lightbeam Health Solutions.

BioGenerator generates revenue through returns on invested capital (exit proceeds, equity appreciation, follow-on participation) and management economics on its evergreen fund structure, which includes BioGenerator Fund I (closed 2017) and two new venture funds totaling $40 million announced in 2025 targeting biotech tools, agtech, and digital health/AI. The firm is led by Senior Managing Director James McCarter (appointed October 2024) and Senior Managing Director Charlie Bolten, who succeeded retiring President Eric Gulve in December 2022. BioGenerator does not sell commercial products; its customers are portfolio companies and the broader St. Louis bioscience ecosystem of academic researchers and entrepreneurs, primarily sourced from Washington University and the Danforth Plant Science Center.

Name

BioGenerator Ventures

Legal name

BioGenerator

Website

https://biogeneratorventures.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

BioGenerator Ventures is the St. Louis-based investment arm of BioSTL that creates, builds, and invests catalytic early-stage capital in life sciences startups spanning human health (therapeutics, diagnostics, medical devices) and agriculture technology, bundling investment with the BioGenerator Labs company-building engine of coaching, lab facilities, and grant support.

Ownership category

akta.pro rank

Product category

Venture Capital and Life Sciences Company Building

NAICS

Other Financial Vehicles (52599), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Investment Advice (6282), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Accelerators & Incubators (Investor-Operated) (FSANAAAM)

akta.pro secondary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Venture capital investing
• Life sciences startups
• Company building resources
• Biotech seed funding
• Agtech investment

Headquarters

HQ city

St Louis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D

Revenue model

1. Investment Returns: BioGenerator Ventures invests capital into early-stage life sciences companies and generates returns through successful exits, follow-on investments, and portfolio company growth. The firm has achieved multiple successful exits including CoverCress (acquired by Bayer), Canopy Biosciences (acquired by Bruker), Confluence Life Sciences (acquired by Aclaris), DiSARM (acquired by Lilly), and others.
2. Portfolio Company Success: Revenue generated through equity appreciation in portfolio companies, IPO exits, and acquisitions. Companies have raised over $2.8B in follow-on capital.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Core offering

BioGenerator Ventures is a venture capital and company-creation firm that makes catalytic early-stage investments in life sciences companies in human health and agriculture. It pairs capital with the BioGenerator Labs engine, providing coaching from Executives in Residence, SBIR/STTR grant training, non-dilutive funding support, shared wet laboratory space at the Cortex Innovation Community and 39N agtech district, talent access through its VC Fellow program, and investor relations support to portfolio companies.

Product overview

BioGenerator Ventures is not a product company but rather a venture capital and company-building organization. It operates as the investment arm of BioSTL, creating and building life sciences companies in human health and agriculture. Its core offering is catalytic investment capital combined with BioGenerator Labs—a suite of company-building resources including coaching from Executives in Residence, SBIR/STTR grant training, shared laboratory facilities at Cortex Innovation Community and 39N agtech district, and talent access. BioGenerator does not develop or sell its own commercial products; rather, it builds portfolio companies and supports their development through pre-company grants, early financing, and ongoing operational support. The named services include investment capital deployment, non-dilutive grant acquisition support, physical lab facilities, coaching and mentorship, and investor relations assistance.

Differentiator

Problem solved

Functional benefit

Products and services

• BioGenerator Ventures (Catalytic Investment Capital) Early-stage venture capital investments into life sciences startups focused on human health and agriculture. BioGenerator often leads first financing rounds and continues to invest across multiple rounds for companies achieving milestones, and syndicates with top global VC, PE, and strategic investors.
• BioGenerator Labs (Company-Building Engine) Integrated suite of company-building resources offered alongside BioGenerator Ventures capital, combining technology, talent, proof-of-concept grants, coaching, grant training, and laboratory space to accelerate the development of portfolio companies.
• SBIR/STTR Grant Winning Program

Quantifiable outcome

• >$60X leverage of BioGenerator invested capital through follow-on funding
• +2 more outcomes

Named customers10 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Four partnerships are on record, tiered core.

• EvogenecoreStrategic or Co-development PartnerCollaboration agreement between Plastomics and Evogene's Ag-Seed division targeting novel insect control traits for soybean using Plastomics' chloroplast transformation technology and Evogene's candidate genes.
• Washington University in St. LouiscoreStrategic or Co-development PartnerKey academic partner for technology licensing; multiple portfolio companies (Wugen, Disarm, SentiAR, others) licensed technology from Washington University.
• Donald Danforth Plant Science CentercoreStrategic or Co-development PartnerPartner providing greenhouse space and specialized capabilities for agricultural technology companies at the 39N innovation district.
• Cortex Innovation CommunitycoreStrategic or Co-development PartnerSt. Louis innovation district housing BioGenerator Labs facilities for life sciences companies.

Scale indicators8 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• ARCH Venture Partners: Chicago-based early-stage biotech venture capital firm that creates and funds life sciences companies. Highly comparable to BioGenerator given shared focus on company creation, Midwest roots, and co-investment history (ARCH has invested in BioGenerator portfolio companies).
• Atlas Venture: Boston-based early-stage biotech venture capital firm that builds and funds life sciences startups from inception. Directly comparable business model — early-stage creation, syndication with larger VCs, focus on human health therapeutics and platforms.
• Flagship Pioneering: Cambridge-based firm that originates and builds biotech companies through a proprietary innovation engine. The closest analog to BioGenerator's 'company-creation plus capital' model, though at significantly larger scale and with more resources.
• 5AM Ventures: Early-stage life sciences venture capital firm focused on creating and funding biotech startups. Comparable in stage focus (seed/Series A), therapeutic breadth, and reliance on syndication with later-stage VCs.
• Frazier Life Sciences: Healthcare-dedicated venture capital firm investing across therapeutics, medical devices, and diagnostics. Comparable in stage and sector concentration, with similar syndication patterns across the life sciences VC ecosystem.
• Versant Ventures: Healthcare-focused venture capital firm with a dedicated company-creation practice (e.g., Inception Sciences). Closely mirrors BioGenerator's combination of catalytic capital and operational company-building support.

Regional players

• RiverVest Venture Partners: St. Louis-based healthcare-focused venture capital firm with deep ties to BioGenerator's portfolio (co-investor in multiple deals). Comparable in healthcare focus and Midwest regional concentration, though without the lab/incubator infrastructure of BioGenerator Labs.

Broad incumbents

• OrbiMed Advisors: Large, established healthcare-dedicated investment firm with funds across venture, growth, and public equity. Comparable sector focus but significantly broader in stage and capital base, often co-investing alongside BioGenerator in later rounds.
• Alexandria Venture Investments: Strategic venture capital arm of Alexandria Real Estate Equities focused on life sciences. Comparable in life sciences focus and role as a long-term capital partner to early-stage biotech, with co-investment history alongside BioGenerator in portfolio companies.

Emerging players

• IndieBio: Investor-operated biotech accelerator providing capital, lab space, and mentorship to early-stage life sciences startups. Direct analog to BioGenerator Labs' company-building engine, though IndieBio focuses more broadly on synthetic biology and operates a shorter program structure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/biogeneratorstl
• Facebookfacebook.com/BioSTL
• LinkedInlinkedin.com/company/biogeneratorventures

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments10 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioGenerator Ventures